PureTech Health plc (NASDAQ:PRTC – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $26.15, but opened at $27.33. PureTech Health shares last traded at $27.48, with a volume of 308 shares traded.
PureTech Health Stock Performance
The firm’s 50 day moving average price is $26.64 and its 200-day moving average price is $23.64.
PureTech Health Company Profile
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
Further Reading
- Five stocks we like better than PureTech Health
- With Risk Tolerance, One Size Does Not Fit All
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
